Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.
Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD. Siegel AB, et al. Among authors: clark garvey s. J Clin Oncol. 2008 Jun 20;26(18):2992-8. doi: 10.1200/JCO.2007.15.9947. J Clin Oncol. 2008. PMID: 18565886 Free PMC article. Clinical Trial.
Monomorphic T-cell post-transplant lymphoproliferative disorders exhibit markedly inferior outcomes compared to monomorphic B-cell post-transplant lymphoproliferative disorders.
Montanari F, Bhagat G, Clark-Garvey S, Seshan V, Zain J, Diefenbach C, McCormick E, Crook M, Conroy M, O'Connor OA. Montanari F, et al. Among authors: clark garvey s. Leuk Lymphoma. 2010 Sep;51(9):1761-4. doi: 10.3109/10428194.2010.500436. Leuk Lymphoma. 2010. PMID: 20807097 No abstract available.
Targeting the Bcl-2 Family in B Cell Lymphoma.
Adams CM, Clark-Garvey S, Porcu P, Eischen CM. Adams CM, et al. Among authors: clark garvey s. Front Oncol. 2019 Jan 8;8:636. doi: 10.3389/fonc.2018.00636. eCollection 2018. Front Oncol. 2019. PMID: 30671383 Free PMC article. Review.
FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression.
Okato A, Utsumi T, Ranieri M, Zheng X, Zhou M, Pereira LD, Chen T, Kita Y, Wu D, Hyun H, Lee H, Gdowski AS, Raupp JD, Clark-Garvey S, Manocha U, Chafitz A, Sherman F, Stephens J, Rose TL, Milowsky MI, Wobker SE, Serody JS, Damrauer JS, Wong KK, Kim WY. Okato A, et al. Among authors: clark garvey s. J Clin Invest. 2024 Jan 16;134(2):e169241. doi: 10.1172/JCI169241. J Clin Invest. 2024. PMID: 38226620 Free PMC article.